CNS Pharmaceuticals Q3 net loss narrows as R&D costs fall
CNSP•CNS Pharmaceuticals reported a third-quarter net loss of $2.5 million, or $0.24 per share, as research and development expenses declined. The company aims to complete its first pipeline-building transaction by year-end 2026.




